[go: up one dir, main page]

WO2024178051A3 - Tryptamine derivatives - Google Patents

Tryptamine derivatives Download PDF

Info

Publication number
WO2024178051A3
WO2024178051A3 PCT/US2024/016630 US2024016630W WO2024178051A3 WO 2024178051 A3 WO2024178051 A3 WO 2024178051A3 US 2024016630 W US2024016630 W US 2024016630W WO 2024178051 A3 WO2024178051 A3 WO 2024178051A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzyloxy
chloride
crystalline
acetamide
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/016630
Other languages
French (fr)
Other versions
WO2024178051A2 (en
Inventor
Andrew R. Chadeayne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caamtech Inc
Original Assignee
Caamtech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caamtech Inc filed Critical Caamtech Inc
Publication of WO2024178051A2 publication Critical patent/WO2024178051A2/en
Publication of WO2024178051A3 publication Critical patent/WO2024178051A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This disclosure relates to 2-[4-(benzyloxy)-lH-indol-3-yl]-2-oxo-A/-(propan-2-yl)acetamide (A/-2-propyl-a-oxo-4-(phenylmethoxy)-lH-indole-3-acetamide), crystalline A/-2-propyl-a-oxo-4-(phenylmethoxy)-lH- indole-3-acetamide, 4-phenoxy-lH-indole (4-benzyloxyindole), crystalline 4-benzyloxyindole, {2-[4- (benzyloxy)-lH-indol-3-yl]ethyl}(propan-2-yl)azanium chloride (4-benzyloxy-/V-isopropyltryptammonium chloride or 4-benzyloxy-NiPT chloride), crystalline 4-benzyloxy-NiPT chloride, and specific crystalline forms thereof, such as crystalline form 1 of /V-2-propyl-a-oxo-4-(phenylmethoxy)-lH-indole-3 acetamide, crystalline form 1 of 4-benzyloxyindole, and crystalline form 1 of 4-benzyloxy-NiPT chloride, to compositions containing the same, and to method of treatment using them.
PCT/US2024/016630 2023-02-22 2024-02-21 Tryptamine derivatives Pending WO2024178051A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363486295P 2023-02-22 2023-02-22
US202363486292P 2023-02-22 2023-02-22
US202363486297P 2023-02-22 2023-02-22
US63/486,292 2023-02-22
US63/486,295 2023-02-22
US63/486,297 2023-02-22

Publications (2)

Publication Number Publication Date
WO2024178051A2 WO2024178051A2 (en) 2024-08-29
WO2024178051A3 true WO2024178051A3 (en) 2024-10-17

Family

ID=92501782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/016630 Pending WO2024178051A2 (en) 2023-02-22 2024-02-21 Tryptamine derivatives

Country Status (1)

Country Link
WO (1) WO2024178051A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145851A1 (en) * 2019-11-19 2021-05-20 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
WO2021179091A1 (en) * 2020-03-12 2021-09-16 Bright Minds Biosciences Inc. 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators
US20210403425A1 (en) * 2020-06-30 2021-12-30 Field Trip Psychedelics Inc. Tryptamine prodrugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145851A1 (en) * 2019-11-19 2021-05-20 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
WO2021179091A1 (en) * 2020-03-12 2021-09-16 Bright Minds Biosciences Inc. 3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators
US20210403425A1 (en) * 2020-06-30 2021-12-30 Field Trip Psychedelics Inc. Tryptamine prodrugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Hallucinogens : Neurochemical, behavioral, and clinical perspectives", 1 January 1984, RAVEN PRESS, US, ISBN: 0-89004-990-4, article DAVID E. NICHOLS, RICHARD A. GLENNON: "Medicinal Chemistry and Structure Activity Relationships of Hallucinogens", pages: 95 - 142, XP009558307 *
LABAN UROŠ, NAEEM MARILYN, CHADEAYNE ANDREW R., GOLEN JAMES A., MANKE DAVID R.: "Synthesis and structure of 4-hydroxy- N -isopropyltryptamine (4-HO-NiPT) and its precursors", ACTA CRYSTALLOGRAPHICA, vol. E79, 1 April 2023 (2023-04-01), pages 280 - 286+24, XP093224882, ISSN: 2056-9890, DOI: 10.1107/S2056989023002098 *

Also Published As

Publication number Publication date
WO2024178051A2 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
NO20012158L (en) Substituted 2-phenylbenzimidazoles, process for preparation and use thereof
CA2443449A1 (en) Pyrazole derivatives for treating hiv
AU2267395A (en) Benzofuran derivatives useful as inhibitors of bone resorption
WO2004098619A3 (en) Treating cartilage / bone conditions with water-soluble strontium salts
MA27809A1 (en) PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES INHIBITORS OF GLYCOGEN-PHOSPHORYLASE
NO20050701L (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
WO2024118767A3 (en) Tryptamine derivatives
MY139027A (en) N-acylamino benzyl ether derivatives
WO2024178051A3 (en) Tryptamine derivatives
DE60318874D1 (en) Pyrazolderivate
WO2024138007A3 (en) Tryptamine derivatives
RU94031479A (en) New application of amino acid derivatives, treatment method, pharmaceutical composition
DE50001301D1 (en) TREATMENT OF MIGRAINE BY ADMINISTRATING ALPHA LIPONIC ACID OR DERIVATIVES THEREOF
AU2003263455A1 (en) Pyrazole amides for treating hiv infections
WO2023201293A3 (en) Tryptamine derivatives
CA2127374A1 (en) Novel derivative of isoindolinone, its preparation and pharmaceutical compositions containing it
WO2023225678A3 (en) Tryptamine derivatives
WO2023278403A3 (en) Crystalline hydrochloride salts of substituted tryptamines
WO2023250465A3 (en) Tryptamine derivatives
WO2024229352A3 (en) Tryptamine derivatives
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
WO2025006964A3 (en) 2-(2-ethoxy-4-propylsulfanyl-5 methoxyphenyl)ethanaminium chloride
IS8306A (en) Eye formulations for treating hypertension
WO2023205768A3 (en) Crystalline quaternary salts of 4-substituted tryptamines
WO2024054973A3 (en) Tryptamine derivatives

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE